论文部分内容阅读
探讨骨肉瘤中雌激素受体（ＥＲ），孕激素受体（ＰＲ）的表达及其与骨肉瘤临床特征的关系。应用免疫组化ＳＰ方法（改良ＳＰ法）对６５例骨肉瘤蜡块组织进行了ＥＲ、ＰＲ检测。所有病人术前均未接受内分泌治疗。骨肉瘤中ＥＲ表达的阳性率为４０％（２６／６５），ＰＲ表达的阳性率为３２３％（２１／６５）；阳性颗粒分布于胞浆和胞核；临床无转移，存活时间长的骨肉瘤中ＥＲ，ＰＲ表达的阳性率高于临床有转移，存活时间短者，差异有显著性（Ｐ＜００５）；不同性别、年龄、发病部位的骨肉瘤中ＥＲ、ＰＲ表达的阳性率差异无显著性（Ｐ＞００５）。说明骨肉瘤中存在ＥＲ、ＰＲ，其阳性率的检测为骨肉瘤生物学行为和病人预后的评估及探讨骨肉瘤内分泌治疗提供理论依据。
To investigate the expression of estrogen receptor (ER) and progesterone receptor (PR) in osteosarcoma and its relationship with clinical characteristics of osteosarcoma. The immunohistochemical SP method (modified SP method) was used to detect ER and PR in 65 cases of osteosarcoma tissue. All patients did not receive endocrine therapy before surgery. The positive rate of ER expression in osteosarcoma was 40% (26/65), and the positive rate of PR expression was 32. 3% (21/65); positive particles were distributed in cytoplasm and nucleus; no metastasis was observed in clinic, and survival time was long. The positive rate of ER and PR expression in osteosarcoma was higher than that in clinical metastasis, and the survival time was shorter (P < 0.05). The expression of ER and PR in osteosarcoma of different sex, age and pathological location There was no significant difference in the positive rate (P>005). It shows that there are ER and PR in osteosarcoma. The detection of the positive rate is the evaluation of the biological behavior of osteosarcoma and the prognosis of patients and provides a theoretical basis for the study of osteosarcoma endocrine therapy.